The effects of tetrandrine (518343) on the proliferative activity of pulmonary fibroblasts were examined to determine if the antifibrotic action of tetrandrine might result from an ability to inhibit fibroblast proliferation. Human fetal lung fibroblasts were incubated with 0 to 11 micromolar (microM) tetrandrine for 6 hours (hr), 0 to 18hr after being stimulated with human serum or plasma plus 50 nanograms per milliliter (ml) platelet derived growth factor (PGDF), tumor necrosis factor alpha (TNFa), or basic fibroblast growth factor (bFGF). The extent of fibroblast proliferation was determined by measuring uptake of tritiated thymidine. Tetrandrine significantly inhibited fibroblast proliferation when added immediately after treatment with PGDF, bFGF, and TNFa in plasma and serum in a concentration dependent manner, the concentrations causing 50% inhibition (IC50s) being 2.5, 1.5, 2.5, and 3.5microM, respectively. Inhibitory effects persisted for up to 14hr after stimulation with the growth factors. Tetrandrine had no effect on fibroblast viability, as no cell killing was detected when the trypan-blue test was applied. Tetrandrine also did not affect cell morphology. Pulmonary fibroblasts stimulated with human serum were treated with 100microM of the calcium (Ca+2) channel blockers nitrendipine or verapamil or the cytoskeletal modifiers cytochalasin- B at 0 to 20 micrograms per milliliter (microg/ml) or taxol at 0 to 20microM. The effects on cellular proliferation were determined. Nitrendipine and cytochalasin-B significantly inhibited fibroblast proliferation in a concentration dependent manner, the IC50s being 25microM and 3.5microg/ml. Cytochalasin-B also caused significant structural deformation of the fibroblasts. Taxol and verapamil did not affect fibroblast proliferation. The authors conclude that tetrandrine directly inhibits proliferation of lung fibroblasts, an effect not explained by Ca+2 channel blockade or modification of the cytoskeletal system. The antifibrotic activity of tetrandrine may be mediated, by a direct inhibition of fibroblastic activity that normally occurs during the development of silicosis.
Links with this icon indicate that you are leaving the CDC website.
The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
You will be subject to the destination website's privacy policy when you follow the link.
CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website.
For more information on CDC's web notification policies, see Website Disclaimers.
CDC.gov Privacy Settings
We take your privacy seriously. You can review and change the way we collect information below.
These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.
Cookies used to make website functionality more relevant to you. These cookies perform functions like remembering presentation options or choices and, in some cases, delivery of web content that based on self-identified area of interests.
Cookies used to track the effectiveness of CDC public health campaigns through clickthrough data.
Cookies used to enable you to share pages and content that you find interesting on CDC.gov through third party social networking and other websites. These cookies may also be used for advertising purposes by these third parties.
Thank you for taking the time to confirm your preferences. If you need to go back and make any changes, you can always do so by going to our Privacy Policy page.